Primary cutaneous CD30-positive large t-cell lymphoma in an 80-year-old man: a case report.
Primary cutaneous CD30-positive large cell lymphoma (CD30+ PCLCL) is a rare subtype of cutaneous T-cell lymphoma (CTCL) that can present in a variety of ways. We report a patient with a three-month history of an enlarging, exophytic mass with two smaller satellite lesions on the left forearm. Biopsy...
| Publicado en: | ISRN Dermatology pp. 1 - 4 |
|---|---|
| Autores principales: | , |
| Formato: | case study pictorial Journal Article |
| Publicado: |
Wiley-Blackwell
2011
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104599713&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104599713 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 20904592 BFDE jtl: ISRN Dermatology issn: 20904592 maglogo: N pubinfo: dt: 2011 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 104599713 104599713 2011365630 NLM22363854 104599713 ppf: 1 ppct: 3 formats: fmt: @attributes: type: P tig: atl: Primary cutaneous CD30-positive large t-cell lymphoma in an 80-year-old man: a case report. aug: au: Hussain, Rehan Bajoghli, Amir affil: School of Medicine, The George Washington University, Washington, DC 20037, USA sug: subj: Lymphoma, T-Cell, Cutaneous Diagnosis Lymphoma, T-Cell, Cutaneous Physiopathology Tumor Necrosis Factor Aged, 80 and Over Histology Methods Male Aged, 80 & over Male ab: Primary cutaneous CD30-positive large cell lymphoma (CD30+ PCLCL) is a rare subtype of cutaneous T-cell lymphoma (CTCL) that can present in a variety of ways. We report a patient with a three-month history of an enlarging, exophytic mass with two smaller satellite lesions on the left forearm. Biopsy of the skin stained positive for CD30, and, after thorough systemic evaluation, a diagnosis of CD30+ PCLCL wasmade.When PCLCL is suspected, it is important to perform immunohistological studies for CD30 types and conduct a thorough workup to rule out systemic LCL. These measures will reduce the use of unnecessarily aggressive chemotherapy regimens for CD30+ PCLCL, an indolent disease with a favorable prognosis. pubtype: Academic Journal doctype: case study pictorial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|